Amgen Knocks Novo Nordisk's Ozempic Stock Rally. Its Stock Is Flying.
Amgen’s progress on its experimental weight-loss drug offered investors a reminder that Novo Nordisk isn’t the only game in town. Amgen’s jumped some 13%. Amgen late Thursday gave some brief but bullish commentary on its drug candidate, MariTide.